IL-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: The TOWARD study 16th Winter Workshop of the Canadian-Rheumatology-Association Genovese, M., Brown, J. P., McKay, J., Nasonov, E., Mysler, E., da Silva, N., Alecock, E., Gomez-Reino, J. J RHEUMATOL PUBL CO. 2008: 1187–87

View details for Web of Science ID 000256503900091